HSP60在大肠腺瘤和大肠癌中表达的临床病理研究

A Clinical Pathological Study on Expressions of HSP60 in Colorectal Carcinoma and Premalignant Lesion

选择大肠癌手术切除癌组织标本56份及同组病例距癌组织外缘3cm内的癌旁组织标本20份,采用免疫组织化学Elivision Plus二步法检测正常大肠黏膜、癌旁组织、大肠腺瘤和大肠癌中热休克蛋白60(HSP60)的表达。结果HSP60在正常大肠黏膜、癌旁组织、大肠腺瘤、大肠癌中表达阳性率分别为27.78%,40%,77.78%,80.36%。各组间比较,HSP60表达的阳性率具有显著性差异(χ2=23.314,P=0.000)。HSP60在大肠癌中的表达可能在大肠癌发生发展中发挥作用,特别在大肠癌恶性演进中以及预后预测中具有重要意义,其可能可以作为独立的生物标志物。

By means of Elivision Plus immunohistochenistry method, the heat shock protein 60 （HSP60） expression in colorectal carcinoma, premalignant lesion and normal tissues is tested. The results showthat the positivity rates of HSP60 in colorectal carcinoma, carcinogenesis and malignant are 27.78%, 40%, 77.78%, 80. 36%, respectively. There are sharp differences in HSP60 expression between the colorectal carcinoma group and the normal group. These results suggest that expressions of HSP60 might play a role in progression of carcinoma and prognosis and might be expected to become independent biomarker.